Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Innoviva, Inc. Common Stock

INVA

Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.

Last trade $18.38
Day change -$0.11 (-0.59%)
Day range $18.30 – $18.93
Volume 500,675
Market cap $1.31B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.31B
Price / earnings
6.79×
Price / book
1.16×
Price / sales
3×
EV / sales
2.26×
EV / EBITDA
4.71×

Profitability

Earnings per share
$2.72
Return on assets
12.58%
Return on equity
17.01%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.23×
Current ratio
15.44×
Quick ratio
14.58×
Cash ratio
11.62×

Cash flow

Price / cash flow
7.16×
Price / free cash flow
7.2×
Free cash flow
$182.51M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for INVA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$106.12M$119.59M$97.99M$114.61M$107.8M$100.28M$88.63M$91.81M
Cost of revenue$21.74M$22.35M$22.16M$38.95M$32.26M$10.59M$15.32M$13.68M
Gross profit$84.38M$97.24M$75.83M$75.67M$75.54M$89.69M$73.32M$78.13M
Selling, general and administrative$37.02M$34.57M$32.44M$32.12M$27.29M$26.41M$27.49M$31.33M
Research and development$5.21M$5.19M$5.24M$4.56M$13.67M$7.98M$4.4M$3.67M
Total operating expenses$42.23M$46.39M$37.68M$36.68M$40.96M$40.94M$31.89M$34.99M
Operating income$42.15M$50.86M$38.15M$38.99M$34.58M$48.75M$41.43M$43.14M
Interest expense-$5.47M-$5.47M-$5.44M-$3.31M-$4.02M-$4.66M-$4.71M-$4.75M
Income before taxes-$97.61M-$108.02M$234.56M$195.04M$97.82M$72.6M-$38.59M$24.69M
Income taxes-$23.72M-$24.6M$47.97M$30.88M$7.91M$8.91M$8M$4.36M
Net income-$73.89M-$83.42M$186.6M$164.15M$89.91M$63.69M-$46.58M$20.33M
Net income attributable to common shareholders-$73.89M-$83.42M$186.6M$164.15M$89.91M$63.69M-$46.58M$20.33M
EBITDA$65.57M$47.83M$48.2M$49.11M$57.71M$45.76M$51.39M$53.14M
Basic earnings per share-$1.03-$1.14$2.52$2.19$1.30$1.01-$0.74$0.32
Diluted earnings per share-$1.03-$1.14$2.22$1.54$1.08$0.77-$0.74$0.23

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Replenish Your Portfolio With These 5 Low Price-to-Sales Stocks

The article identifies five stocks with low price-to-sales ratios and strong fundamentals as potential value investments: Innoviva (INVA), HF Sinclair (DINO), Par Pacific (PARR), Green Plains (GPRE), and PBF Energy (PBF). All five companies demonstrate improving margins, solid business momentum, and favorable financial metrics, making them suitable candidates for value-focused investors seeking undervalued opportunities.

Zacks Investment Research

Is Innoviva (INVA) Stock Undervalued Right Now?

Zacks identifies Innoviva (INVA) as an attractive value investment opportunity, citing its Zacks Rank #2 (Buy) rating and Value grade of A. The company trades at a P/E ratio of 10.12, significantly below its industry average of 19.36, and demonstrates favorable valuations across multiple metrics including P/S and P/CF ratios, suggesting the stock is undervalued relative to its earnings prospects.

Zacks Investment Research

INVA or MRK: Which Is the Better Value Stock Right Now?

A comparison of Innoviva (INVA) and Merck (MRK) as value investment opportunities in the large cap pharmaceuticals sector. Innoviva receives a Zacks Rank #2 (Buy) with a Value grade of A, featuring a forward P/E of 14.69 and P/B ratio of 1.21. Merck holds a Zacks Rank #3 (Hold) with a Value grade of D, showing a forward P/E of 52.92 and P/B ratio of 8.05. Based on valuation metrics and earnings revision trends, Innoviva is positioned as the better value opportunity.

Zacks Investment Research

Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates

Pfizer reported Q3 2026 earnings of $0.87 per share, beating consensus estimates of $0.72 by 20.83%, with revenues of $16.58 billion slightly exceeding expectations. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, and the Large Cap Pharmaceuticals industry ranks in the bottom 36% of sectors, suggesting near-term performance in line with the market.

Zacks Investment Research

AbbVie (ABBV) Tops Q3 Earnings and Revenue Estimates

AbbVie reported Q3 2026 earnings of $3.82 per share, beating consensus estimates of $3.74, with revenues of $17.4 billion exceeding expectations. However, the stock carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The Large Cap Pharmaceuticals industry ranks in the bottom 14% of Zacks industries. Innoviva is expected to report earnings of $0.49 per share, representing a 54.6% year-over-year decline.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Sep 8, 2015$0.25Sep 30, 2015recurring
Jun 10, 2015$0.25Jun 30, 2015recurring
Mar 10, 2015$0.25Mar 31, 2015recurring
Nov 21, 2014$0.25Dec 23, 2014recurring
Aug 26, 2014$0.25Sep 18, 2014unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 17, 20131-for-100reverse split